Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis - Wikidata - awgldk - TriplyDB

Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis

Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis

http://www.wikidata.org/entity/Q24800661

about

Overview of the biology of type I interferons CD97 neutralisation increases resistance to collagen-induced arthritis in mice Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts Exacerbated innate host response to SARS-CoV in aged non-human primates Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency The protective effect of intrasplenic transplantation of Ad-IL-18BP/IL-4 gene-modified fetal hepatocytes on ConA-induced hepatitis in mice Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model.Two novel α7 nicotinic acetylcholine receptor ligands: in vitro properties and their efficacy in collagen-induced arthritis in mice.A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis.Role of interferon regulatory factor 7 in serum-transfer arthritis: regulation of interferon-β production Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.Therapeutic targeting of the inflammome.Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide Should we inhibit type I interferons in sepsis?Arthritis gene therapy and its tortuous path into the clinic.Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway.Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.Interleukin 27: a double-edged sword for offense and defense.Vitamin D endocrine system and osteoblasts.Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21.Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.Type I interferon in organ-targeted autoimmune and inflammatory diseases.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.The Regulation of Immune Responses by DC Derived Type I IFN.Emerging role of endosomal toll-like receptors in rheumatoid arthritis Vitamin D and gene networks in human osteoblasts.Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Human cartilage fragments in a composite scaffold for single-stage cartilage repair: an in vitro study of the chondrocyte migration and the influence of TGF-β1 and G-CSF.Optimization of current and future therapy for autoimmune diseases.A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats.The aggravation of arthritis by periodontitis is dependent of IL-17 receptor A activation.Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats.FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development.The circadian clock regulates inflammatory arthritis.Evaluation of destruction in a collagen-induced arthritis rat model: Bony spur formation.

P2860

Q21195364-317AAEE4-6EDF-4619-BF76-9AF5C3CFA1BA Q21195425-57D34D2A-69B5-4230-BE76-0DDF6593A89F Q26828486-863B6862-207C-42BE-A1CF-27646EEB8AB7 Q27315954-FA779204-BA7D-4340-9DC3-4C8A4B6BC56E Q28271779-B11EF036-5BBE-4083-8F73-43E997EA7813 Q33834191-FC222550-B755-491B-9CC5-CAA0C7138D3B Q34358419-AE213879-2938-4098-AA25-0F9BAC7BCB92 Q34478537-F94ED042-05DE-49EF-B8B4-F565ACCA68E0 Q34630072-9A14B9BA-A63E-4FFD-A48E-5856512372F1 Q34751981-53D84201-0DB0-4E3F-8C76-B2E4B5CCF997 Q35548484-C3E7CBFF-774F-4ABF-8565-1A59DA0E5EA2 Q35554739-8C251A66-734B-4114-BE89-5FCC773210D4 Q35673189-44E76B14-9ABC-4B17-9EF7-2CCFA46D025D Q35791167-4DD19316-72F1-462B-A4BD-967C2A6D7478 Q36360719-44D0748F-F596-41C7-B607-F679DE3E7ABD Q36490256-C6FA12E6-AD96-4C52-9275-B262BBF478EF Q36550855-166C860C-8865-44D1-B195-BF3430F63F88 Q36603706-7A1D57BB-4D3F-4F1B-B586-5CB8934D7BE6 Q36698181-55DDBA08-91AC-4BBE-97C0-B493C9F84928 Q36723165-A44F0909-9C96-4ACC-8EBD-793CA03C10D1 Q37058559-F17A2C76-A77C-4603-851E-2DAB33E7CAAA Q37269317-616C5442-6FBA-49BA-BCDE-C784C8A7F857 Q37607910-B9E67B41-617C-4816-BAE3-C9DE13A4DB48 Q37620405-9D1D89F6-EACB-42E6-A0DA-D64C3A196835 Q37639837-4890E4AD-A990-4621-84DB-765E11110C3D Q37808291-EE612249-B363-4A53-8113-921B85CB36F3 Q37838003-5F731732-E356-4665-844E-BE7324F3FDE0 Q38004932-03848F77-2EDB-4EAE-8E9C-D498D8D86606 Q38102693-8052ADF3-EC92-46C2-A126-6FE1E5B65A2C Q38182971-9E69AFDD-6A8C-4CAC-9D38-E238F3A1A76B Q38208297-4EB53292-85CE-497A-8F39-12CE54F9AB0F Q38335622-45F0740F-EA41-4E26-93DD-BC17E0494398 Q39521836-CE23DD90-821C-4955-9076-CD7034C39422 Q39666645-E2237AAB-EF83-4312-A6D5-7384EEBC1CC7 Q39915429-B52A4D85-EAD3-4B2F-9127-ECC347B04C66 Q40215319-DEE57B40-AA0E-4401-B16D-A98A0583DB6D Q41036628-59FFEB90-511D-44D3-8C92-BD15D0F7C0E5 Q41183700-D17C04E6-C7A7-4D1E-A45A-F7485CC164E2 Q41481270-83661AFD-E957-45FA-BE1A-57BF33EB2149 Q41672116-8DBB50E4-595C-4324-8757-391C631E7E9A

P2860

Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis

http://www.wikidata.org/entity/Q24800661

description

2004 nî lūn-bûn

@nan

2004 թուականին հրատարակուած գիտական յօդուած

@hyw

2004 թվականին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

Treatment with recombinant int ...... model of rheumatoid arthritis

@ast

Treatment with recombinant int ...... model of rheumatoid arthritis

@en

Treatment with recombinant int ...... model of rheumatoid arthritis

@nl

type

label

Treatment with recombinant int ...... model of rheumatoid arthritis

@ast

Treatment with recombinant int ...... model of rheumatoid arthritis

@en

Treatment with recombinant int ...... model of rheumatoid arthritis

@nl

prefLabel

Treatment with recombinant int ...... model of rheumatoid arthritis

@ast

Treatment with recombinant int ...... model of rheumatoid arthritis

@en

Treatment with recombinant int ...... model of rheumatoid arthritis

@nl

P1433

Q24800661-5D4E2CA0-7C84-4EEB-B913-218E2BB51EA7

P1476

Q24800661-DFFE79BD-D821-413D-A2B1-A36414DF9715

P2093

Q24800661-076B16CF-D52C-47C4-BB9C-1BC62B094C47

Q24800661-07EDAEB7-C0A4-4C7A-B24D-E0EE6F00EB41

Q24800661-2587CFD3-A390-48E5-A1D7-75BB6D4D5C99

Q24800661-688DB887-0B33-4788-89F7-03B0B094596A

Q24800661-85122A9E-F7FF-489C-A248-7809B89CB9A8

Q24800661-A5911819-3925-45AB-BCD1-8A986B1B3455

Q24800661-AA2F153B-B14C-432C-80BA-ADA253A23459

P2860

Q24800661-13B52280-7D05-4387-90C2-47B7F9FA7A14

Q24800661-226954A6-67E8-4AE9-8076-241EF9EDC3E7

Q24800661-351D1BE4-159C-4647-A5DC-4131A977C4A7

Q24800661-38DD78B7-E764-4061-AB20-8751F0773A91

Q24800661-3D05E6B8-C769-43C9-9B71-94F9FDB03D82

Q24800661-517A4724-7152-475E-8930-745F18FFAB17

Q24800661-518A2F70-28E0-43AB-AE88-D55B0299DEBD

Q24800661-533BF342-DAFD-45C7-A90E-8E3C46DC893B

Q24800661-59E8453E-76E5-4C13-9EF4-A607D84DD884

Q24800661-5B02B0BE-8B52-457F-86B6-11396F59E451

P2888

Q24800661-7A0DD1C7-7FBF-4E7D-B277-9BE7A2F75D08

P304

Q24800661-F5D4F7B2-E035-447B-AF4F-C9D11D7AC594

P31

Q24800661-80CE8D2D-638B-4844-A6A0-1D3A724EB1F7

P3181

Q24800661-3F66E070-7827-48A2-802F-08B661090A23

P356

Q24800661-E4097964-4DFF-46B0-84B9-5D1F4E145504

P407

Q24800661-F89FB033-9912-4BA0-8682-40CBAB98C015

P433

Q24800661-BF5C157D-0AF4-4754-B61E-37D269BC7464

P478

Q24800661-B2201E2B-7583-4BEC-A588-0554BE6AE95B

P577

Q24800661-27EFD62D-E6AF-4950-971E-630104FAD68A

P5875

Q24800661-3957630D-03C6-4C8A-8665-94E83FF0A20C

P6179

Q24800661-883B2A3D-45DC-49DF-B20E-D18915C50384

P698

Q24800661-81FE0536-3447-4E4F-A29E-B5743C28D8BD

P921

Q24800661-7FD0FB75-5DE4-4300-BE7D-9D3CD0663B6F

Q24800661-8A79F20C-10E9-4C2E-8549-BAFB29796441

P932

Q24800661-931C05D3-DA15-458F-BF00-C7E5F047EAEE

P3181

P356

P1433

Arthritis Research and Therapy

P1476

Treatment with recombinant int ...... model of rheumatoid arthritis

@en

P2093

Christine Plater-Zyberk

http://www.w3.org/2001/XMLSchema#string

Judith van Holten

http://www.w3.org/2001/XMLSchema#string

Kris Reedquist

http://www.w3.org/2001/XMLSchema#string

Margriet J Vervoordeldonk

http://www.w3.org/2001/XMLSchema#string

Pascale Sattonet-Roche

http://www.w3.org/2001/XMLSchema#string

Paul P Tak

http://www.w3.org/2001/XMLSchema#string

Tom J M Smeets

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626

Interferon-beta for treatment of rheumatoid arthritis?

How cells respond to interferons

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

NF-kappaB: a key role in inflammatory diseases

The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis.

Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis.

Effect of interleukin 17 on proteoglycan degradation in murine knee joints.

Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts

P2888

P304

R239-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4325431

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/AR1165

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8564323

http://www.w3.org/2001/XMLSchema#string

P6179

1015023155

http://www.w3.org/2001/XMLSchema#string

P698

15142270

http://www.w3.org/2001/XMLSchema#string

P921

P932

416442

http://www.w3.org/2001/XMLSchema#string